Pisters Katherine M W
University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Clin Adv Hematol Oncol. 2003 Sep;1(9):533-7.
Survival rates following complete resection for patients with non-small-cell lung cancer are disappointing. Only 60-70% of patients with stage I disease (no lymph node involvement) are expected to survive 5 years. Attempts to improve survival have included the use of chemotherapy, radiation, or both before or after surgery. The majority of randomized trials examining the use of postoperative therapies have not found a survival benefit. Many of these trials have enrolled small numbers of patients and have been underpowered to detect small, but significant, survival differences. Recent data from large, randomized international trials have yielded conflicting results. The use of postoperative therapy should continue to be studied in clinical trials and a new meta-analysis incorporating results from recently completed randomized trials should be conducted.
非小细胞肺癌患者完全切除后的生存率令人失望。只有60%-70%的I期疾病（无淋巴结受累）患者有望存活5年。为提高生存率所做的努力包括在手术前或手术后使用化疗、放疗或两者兼用。大多数检验术后治疗效果的随机试验未发现生存获益。这些试验中有许多纳入的患者数量较少，没有足够的能力检测出虽小但显著的生存差异。来自大型国际随机试验的最新数据产生了相互矛盾的结果。术后治疗的应用应继续在临床试验中进行研究，并且应该进行一项纳入最近完成的随机试验结果的新的荟萃分析。
